Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Synthesis and Evaluation of Chroman-4-One Linked to N-Benzyl Pyridinium Derivatives As New Acetylcholinesterase Inhibitors Publisher Pubmed



Arab S1 ; Sadatebrahimi SE1 ; Mohammadikhanaposhtani M1 ; Moradi A2 ; Nadri H2 ; Mahdavi M1 ; Moghimi S1 ; Asadi M1 ; Firoozpour L3 ; Piralihamedani M1 ; Shafiee A1 ; Foroumadi A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medicinal Chemistry, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medicinal Chemistry, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  3. 3. Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Archiv der Pharmazie Published:2015


Abstract

A novel series of chroman-4-one derivatives containing the N-benzyl pyridinium moiety were designed, synthesized, and evaluated for their acetylcholinesterase (AChE) inhibitory activities. Among the various synthesized compounds, (E)-1-(2,3-dibromobenzyl)-4-((7-ethoxy-4-oxochroman-3-ylidene)methyl)pyridinium bromide (8l) depicted the most potent anti-AChE activity (IC50=0.048μM). In addition, the molecular modeling study allowed us to detect possible binding modes that are in full compliance with the observed results through in vitro experiments. A novel series of chroman-4-one derivatives bearing N-benzyl pyridinium derivatives (8a-l) were synthesized and evaluated in vitro for their acetylcholinesterase inhibitory activities. The most promising compound, (E)-1-(2,3-dibromobenzyl)-4-((7-ethoxy-4-oxochroman-3-ylidene)methyl)pyridinium bromide 8l, showed an IC50 value of 0.048μM. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.